STOCK TITAN

Serina CSO granted 85,558 stock options

Serina Therapeutics, Inc. Chief Scientific Officer Moreadith Randall received a grant of stock options covering 85,558 shares of common stock.

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Serina Therapeutics, Inc. Chief Scientific Officer Moreadith Randall received a grant of stock options covering 85,558 shares of common stock. The options have an exercise price of $1.89 per share and expire on May 21, 2036.

These options were granted at no upfront cost and are held directly. According to the vesting terms, 12/48ths of the options vest twelve months after the vesting commencement date, with an additional 1/48th vesting each month thereafter until fully vested.

Positive

  • None.

Negative

  • None.
Insider Moreadith Randall
Role Chief Scientific Officer
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 85,558 $0.00 $0.00
Holdings After Transaction: Stock Option (right to buy) — 85,558 contracts (Direct)
Footnotes (1)
  1. F1. Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested.
Options granted 85,558 options Grant to Chief Scientific Officer on May 21, 2026
Exercise price $1.89 per share Strike price for stock option grant
Expiration date May 21, 2036 Option term for stock option grant
Underlying shares 85,558 shares Common stock underlying the options
Initial vesting 12/48ths after 12 months Cliff vesting one year after vesting commencement date
Ongoing vesting 1/48th monthly Monthly vesting after initial one-year cliff
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 1.8900"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"12/48ths of the shares subject to the option shall vest twelve months"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: 2036-05-21T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
underlying security financial
"underlying_security_title: Common Stock"

FAQ

What insider transaction did Serina Therapeutics (SER) report for Moreadith Randall?

Serina Therapeutics reported that Chief Scientific Officer Moreadith Randall received a grant of 85,558 stock options. These options give the right to buy common shares at a fixed price and are part of the executive’s equity-based compensation package.

What is the exercise price of the new stock options granted at Serina Therapeutics (SER)?

The newly granted stock options have an exercise price of $1.89 per share. This means the executive can later buy Serina Therapeutics common stock at $1.89, regardless of the future market price, once the options vest.

When do the Serina Therapeutics (SER) stock options granted to Moreadith Randall expire?

The stock options granted to Moreadith Randall expire on May 21, 2036. If the options are not exercised by that date, they lapse and can no longer be used to purchase Serina Therapeutics common stock.

How do the new Serina Therapeutics (SER) stock options to the CSO vest over time?

The options vest over four years with a one-year cliff. Twelve forty-eighths vest twelve months after the vesting commencement date, and one forty-eighth vests monthly thereafter until all 85,558 options are fully vested.

Is the Serina Therapeutics (SER) stock option grant to the CSO an open-market purchase or compensation?

The transaction is a compensation-related grant, not an open-market purchase. The options were awarded at no upfront cost to the executive as part of equity compensation, with value realized only if exercised above the $1.89 strike price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Moreadith Randall

(Last)(First)(Middle)
601 GENOME WAY, SUITE 2001

(Street)
HUNTSVILLE ALABAMA 35806

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Serina Therapeutics, Inc. [ SER ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Scientific Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$1.8905/21/2026A85,558 (1)05/21/2036Common Stock85,558$085,558D
Explanation of Responses:
1. Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested.
Remarks:
/s/ Randall Moreadith05/26/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading